Persistent Market Expansion and Broad Adoption Highlight ARS Pharmaceuticals Q1 2026 Report

Robust neffy® U.S. Sales Drive Revenue Surge Amid Investment in Growth

ARS Pharmaceuticals (NASDAQ: SPRY) reported total Q1 2026 revenue of $22.68 million, a near-tripling versus last year’s Q1 result. Leading the charge is neffy®—the company’s needle-free epinephrine nasal spray—accounting for $17.45 million in U.S. net product sales. This innovative option is quickly reshaping emergency care for allergic reactions, winning prescriber and patient adoption across the country.

According to the latest update, more than 28,000 healthcare providers have prescribed neffy, with about half writing repeat prescriptions. Over 10,000 schools have now joined the neffyinSchools program, each receiving two cartons for emergency use, resulting in more than 200 reported real-world uses. Repeat prescribers and high-decile accounts drive much of the demand momentum, and more widespread insurance access is on the horizon as major pharmacy benefit managers, including CVS Caremark, near formulary decisions for July.

Heavy Investment in Commercialization and R&D Sets Up Longer-Term Growth

Despite surging revenue, ARS Pharma reported a net loss of $60.62 million for Q1 2026, or ($0.61) per share, mainly due to substantial selling, general, and administrative (SG&A) expenses totaling $72.2 million. The bulk of this outlay went to expanding direct-to-consumer marketing and growing the U.S. sales force from 106 to 148 representatives, positioning the company for deeper market penetration.

Research and development expenses reached $4.34 million in the quarter as the company continued developing next-generation intranasal epinephrine treatments, including the ongoing Phase 2b trial for chronic spontaneous urticaria (CSU). Interim results from this study are expected in Q4 2026, with a pivotal Phase 3 trial targeted for mid-2027.

International Access Gains and Regulatory Milestones Extend Opportunity

Beyond the U.S., neffy’s global reach expanded with milestones in Canada and the EU. Health Canada’s approval of neffy came in April, and commercial launch is set for later this year via ARS’s partner ALK. In Europe, EURneffy® 1 mg earned marketing authorization, targeting pediatric patients, with ALK handling EU commercialization. These approvals contributed to $2.49 million in international collaboration revenue and $2.74 million in supply revenue, further diversifying ARS’s income stream.

Financial Position Remains Solid Despite Operating Loss

As of March 31, 2026, ARS Pharma held $201 million in cash, cash equivalents, and short-term investments, supporting management’s confidence that its runway will last through break-even cash flow. The expansion has weighed on balance sheet equity, now at $61.31 million, down from $114.26 million at the 2025 close, reflecting ongoing investments in growth. However, continued strong cash reserves offer a cushion for ARS’s upcoming commercial and clinical milestones.

Payer Access, School Programs, and Product Indications Show Broadening Adoption

Key payor adoption advances continue as CVS Caremark formulary inclusion for neffy is expected by July, and Florida’s Medicaid program recently joined nine states providing unrestricted coverage. The company anticipates a majority of states will follow by early 2027. Additionally, FDA has removed age criteria for 1 mg neffy, widening its eligible patient population to all adults and children over 33 lbs.

What to Watch Next: Cash Burn Versus Market Growth

While the company’s sales momentum and access expansion are notable, investors may focus on when ARS Pharma can translate top-line growth into operating leverage. Direct-to-consumer investments, expanded sales efforts, and global launches require significant upfront spend, but growing insurance adoption and recurring prescription renewals could set the stage for improved financial results moving forward.

For now, ARS’s leadership remains confident in reaching cash flow break-even without needing to raise additional funds. The market will be watching how new demand shapes up in the second half of 2026 as payor and patient adoption further accelerate. Key milestones, such as interim clinical readouts and international launches, add additional catalysts for the remainder of the year.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI